Birch Hill's Medwell ups stake in venture-backed Mimetogen
Edmonton, Alberta-based Medwell Capital Corp. (TSX-V: MWC) has increased its stake in Montréal's Mimetogen Pharmaceuticals Inc., a developer of treatments for neurodegenerative diseases of the eye. In total, Medwell will have invested $2.8 million and will own 11.3% of the company on a fully diluted basis. Medwell, a provider of capital and advisory services to the healthcare industry, is a portfolio company of buyout firm Birch Hill Equity Partners. Mimetogen is backed by venture capital firms, including iNovia Capital and VIMAC Ventures.
18 July 2013•2 mins read
